Ruxolitinib

Ruxolitinib is a targeted medicine belonging to the Janus kinase (JAK) inhibitor class. It inhibits JAK1 and JAK2, enzymes involved in signalling pathways that regulate blood-cell production, inflammation, and immune activity. By reducing excessive JAK signalling, ruxolitinib can help control disease-related symptoms, reduce spleen enlargement in certain blood disorders, and suppress harmful immune responses in graft-versus-host disease (GVHD), a complication that can occur after an allogeneic stem-cell transplant.

Ruxolitinib is available in oral formulations for systemic treatment and as a topical cream for selected inflammatory skin conditions. The appropriate formulation, dose, and treatment schedule depend on the diagnosis, age, blood counts, organ function, previous therapies, and the applicable regulatory approval. Oral ruxolitinib is used for conditions including myelofibrosis, polycythaemia vera, and selected cases of acute or chronic GVHD. In the United States, topical ruxolitinib cream is also approved for specific patients with atopic dermatitis and nonsegmental vitiligo.

Treatment requires appropriate medical supervision because ruxolitinib can affect blood-cell counts and immune function. Monitoring helps clinicians assess treatment response, identify infections or other adverse effects, and determine whether dose adjustment or interruption is needed. Its benefits and risks should be evaluated according to the specific condition being treated and the current local prescribing information.

Ruxolitinib was developed as a targeted inhibitor of JAK-mediated signalling, following the identification of abnormalities in this pathway in myeloproliferative neoplasms, including diseases associated with JAK2 mutations. The US Food and Drug Administration (FDA) first approved oral ruxolitinib in 2011 for myelofibrosis. The European Medicines Agency (EMA) authorised Jakavi in 2012, with subsequent extensions to indications including polycythaemia vera and graft-versus-host disease. The COMFORT-I and COMFORT-II phase III trials established important evidence for ruxolitinib in myelofibrosis, while the RESPONSE programme evaluated its use in polycythaemia vera. The REACH trials supported its use in steroid-refractory GVHD. In the United States, topical ruxolitinib cream was approved in 2021 for eligible patients with atopic dermatitis and in 2022 for nonsegmental vitiligo. These approvals apply to different formulations and clinical settings; approved ages, indications, and dosing instructions vary by jurisdiction and product.

Oral ruxolitinib is used for adults with intermediate- or high-risk myelofibrosis, including primary myelofibrosis and myelofibrosis developing after polycythaemia vera or essential thrombocythaemia. It is also used for adults with polycythaemia vera who have an inadequate response to or cannot tolerate hydroxyurea. Depending on the local approval, oral treatment may be indicated for acute or chronic GVHD that has not responded adequately to corticosteroids or other systemic therapies; authorised age limits differ between the United States and European Union. Topical ruxolitinib cream has separate indications in the United States for short-term and non-continuous chronic treatment of eligible patients with mild-to-moderate atopic dermatitis and for repigmentation in nonsegmental vitiligo. The oral and topical formulations are not interchangeable. Selection depends on diagnosis, disease severity, previous treatment, age, and the approved product information.

Oral ruxolitinib is taken by mouth, with dosing determined by the condition being treated, baseline platelet count, blood-cell counts, organ function, age, and interacting medicines. For adult myelofibrosis, the initial dose is selected according to platelet count; polycythaemia vera commonly starts at 10 mg twice daily under the European product information. GVHD dosing depends on the formulation, age group, and applicable prescribing guidance. Treatment may require dose reductions, interruptions, or gradual withdrawal planning according to the indication and clinical circumstances; patients should not stop oral therapy abruptly without medical advice. Topical ruxolitinib cream is applied as a thin layer to eligible affected skin areas according to the product-specific instructions, including limits on treated body-surface area and quantity. Treatment duration and ongoing use should be reviewed by the prescriber, with monitoring appropriate to the formulation and indication.

Common adverse effects of oral ruxolitinib include anaemia, low platelet counts, reduced neutrophil counts, bruising, dizziness, headache, and infections. Some patients may experience changes in cholesterol or liver enzyme levels. In GVHD, the underlying condition and concurrent immunosuppressive treatments can also contribute to symptoms and infection risk. With topical ruxolitinib, application-site acne, redness, itching, or irritation may occur. Side effects vary according to the formulation, dose, underlying disease, and individual health status. Many can be managed through monitoring, supportive care, or clinician-directed dose adjustment. Patients should report persistent symptoms, unusual bruising, bleeding, fever, or signs of infection, and should not change their treatment schedule without consulting their healthcare professional.

Ruxolitinib can cause significant reductions in blood-cell counts, including anaemia, thrombocytopenia, and neutropenia. Serious infections, including tuberculosis, herpes zoster, and opportunistic infections, have been reported with JAK inhibitors. Other important risks associated with systemic JAK inhibitor treatment include certain malignancies, major adverse cardiovascular events, and thrombosis; individual risk depends on the patient's condition and other factors. Topical ruxolitinib also carries important class-related warnings in its US prescribing information, although systemic exposure differs from oral treatment. Clinicians should assess persistent cytopenias, suspected serious infection, or other significant adverse reactions and determine whether treatment interruption, dose modification, or discontinuation is appropriate. Patients should promptly report fever, unusual bleeding, chest pain, sudden breathlessness, or one-sided limb swelling.

Before starting oral ruxolitinib, clinicians should obtain a complete blood count and assess relevant liver and renal function, infection history, vaccination status, and concomitant medicines. Screening for tuberculosis and viral hepatitis may be appropriate according to clinical risk and local guidance. Patients with active serious infections require careful assessment before treatment. Ruxolitinib exposure can be affected by medicines that inhibit or induce CYP3A4 or, in some circumstances, CYP2C9; medication reconciliation is important before starting or changing therapy. Live vaccines should generally be avoided during treatment with systemic immunosuppressive therapy unless the treating specialist advises otherwise under applicable guidance. For topical treatment, clinicians should follow formulation-specific restrictions, precautions, and monitoring advice. Pregnancy, breastfeeding, older age, cardiovascular risk, previous thrombosis, and a history of malignancy may affect treatment decisions. Precautions differ between oral and topical formulations, so their prescribing information should be reviewed separately.

Confirm the diagnosis, intended formulation, and locally approved indication before prescribing or dispensing ruxolitinib. For oral treatment, document baseline blood counts and relevant organ-function results, review infection risks and vaccination history, and assess potential drug interactions. Monitor complete blood counts regularly, particularly during initial treatment and after dose changes, and follow the product-specific recommendations for dose modification. Counsel patients not to stop oral treatment or change doses without professional advice, and explain symptoms that need prompt medical assessment, including fever, unusual bruising, bleeding, and signs of thrombosis. For topical ruxolitinib, demonstrate correct application and reinforce limits on treated skin area, quantity, and duration where specified. Coordinate care with haematology, oncology, dermatology, or transplant teams as appropriate. Because dosing, age limits, and warnings differ by formulation and jurisdiction, use the current local prescribing information when making treatment decisions.